MC
CELGZ

Muhlenkamp & Co’s Celgene Corporation Contingent Value Rights CELGZ Stock Holding History

Muhlenkamp & Co’s Portfolio CELGZ Stock Details CELGZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-15,810
Closed -$18K – 60
2016
Q1 		$18K Sell
15,810
-1,675
-10% -$2.24K 0.01% 52
2015
Q4 		$21K Buy
17,485
+1,675
+11% +$2.23K 0.01% 58
2015
Q3 		$25K Buy
15,810
+3,225
+26% +$6.22K 0.01% 63
2015
Q2 		$26K Buy
+12,585
New +$32.2K 0.01% 69

Other funds holding CELGZ

CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
FA
FCG Advisors Chatham, New Jersey $425M AUM 12.09% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
UAS
United Asset Strategies Garden City, New York $1.41B AUM 27.73% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
AC
Ascend Capital Orinda, California $1.99B AUM 10.36% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
CL
CSS LLC Chicago, Illinois $2.09B AUM 59.56% 1-Year Est. Return

Muhlenkamp & Co's CELGZ Position: Q2 2016 in Review

Muhlenkamp & Co sold out of Celgene Corporation Contingent Value Rights (CELGZ) in Q2 2016, closing a stake of 15,810 shares — an estimated $18K sold.

Muhlenkamp & Co first reported a position in CELGZ in Q2 2015 and held it in 4 quarters. The position peaked at $26K in Q2 2015. 26 funds tracked by Wall St. Rank hold CELGZ as of Q2 2016.

  • Muhlenkamp & Co reported no remaining Celgene Corporation Contingent Value Rights position as of Q2 2016 after selling out during the quarter.
  • Muhlenkamp & Co sold 15,810 Celgene Corporation Contingent Value Rights shares in Q2 2016, an estimated $18K.
  • Muhlenkamp & Co first reported a position in Celgene Corporation Contingent Value Rights in Q2 2015 and held it in 4 quarters.
  • Muhlenkamp & Co's Celgene Corporation Contingent Value Rights position peaked at $26K in Q2 2015.
  • 26 funds tracked by Wall St. Rank held Celgene Corporation Contingent Value Rights as of Q2 2016.

Based on Muhlenkamp & Co's 13F filing for Q2 2016, filed 9 Aug 2016.